Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome  Ernesto Bosch,

Slides:



Advertisements
Similar presentations
Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.
Advertisements

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.
Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization.
Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis 
Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.
José Bellver, M. D. , Marco A. B. Melo, M. D. , Ernesto Bosch, M. D
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating.
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Impact of circulating levels of total and bioavailable serum vitamin D on pregnancy rate in egg donation recipients  Alberta Fabris, M.D., Alberto Pacheco,
Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression 
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
Differences in in vitro fertilization (IVF) outcome between white and black women in an inner-city, university-based IVF program  Fady I Sharara, M.D.,
Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy  Ewa Nowak-Markwitz,
Clinical experience and perinatal outcome of blastocyst transfer after coculture of human embryos with human endometrial epithelial cells: a 5-year follow-up.
The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count  Simone L. Broer, B.Sc., Ben Willem J.
Modified natural cycle in in vitro fertilization
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis 
Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.
Martin D. Keltz, M. D. , Josh C. Skorupski, M. D. , Katrina Bradley, M
Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles  Tsung-Hsien.
Prevalence of premature urinary luteinizing hormone surges in women with regular menstrual cycles and its effect on implantation of frozen-thawed embryos 
Six years' experience in ovum donation using vitrified oocytes: report of cumulative outcomes, impact of storage time, and development of a predictive.
Robert F. Casper, M.D.  Fertility and Sterility 
Cumulative live-birth rates per total number of embryos needed to reach newborn in consecutive in vitro fertilization (IVF) cycles: a new approach to.
Early pregnancy losses in in vitro fertilization and oocyte donation
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review  Carlo Alviggi, M.D., Ph.D., Alessandro Conforti,
Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.
David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D. 
From partner's desk to iPad
A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome  Uma Deve Gordon, M.D., Robert F Harrison,
Obesity reduces uterine receptivity: clinical experience from 9,587 first cycles of ovum donation with normal weight donors  José Bellver, M.D., Antonio.
Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized.
Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis  Rina Agrawal,
Personalized prediction of first-cycle in vitro fertilization success
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol  Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,
Fertility and Sterility
Why do couples discontinue in vitro fertilization treatment
José Bellver, M. D. , Yanira Ayllón, M. D. , Marcos Ferrando, M. D
Decreased levels of interleukin-18 in peritoneal fluid but not in serum of patients with endometriosis  Xinmei Zhang, M.D., Jun Lin, M.D., Yuli Qian,
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Efficacy of luteinizing hormone activity in patients undergoing in vitro fertilization and treated only with low-dose recombinant choriogonadotropin alfa.
The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.
Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization  David W. Schmidt, M.D.,,
Paolo Moghetti, M.D.  Fertility and Sterility 
Value of the serum estradiol level on the day of human chorionic gonadotropin injection and on the day after in predicting the outcome in natural in vitro.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas.
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.
Use of serum inhibin A and human chorionic gonadotropin measurements to predict the outcome of in vitro fertilization pregnancies  Erik Hauzman, M.D.,
Thin endometrial stripe does not affect likelihood of achieving pregnancy in clomiphene citrate/intrauterine insemination cycles  Albert Asante, M.D.,
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.
Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy  Eman A. Elgindy,
Ongoing pregnancy rates in intrauterine insemination are affected by late follicular- phase progesterone levels  Antonio Requena, M.D., María Cruz, Ph.D.,
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:
In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study  Carmen Rubio,
Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment  Daniel Bodri, M.D., M.Sc.,
Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.
Presentation transcript:

Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome  Ernesto Bosch, M.D., Iván Valencia, M.D., Ernesto Escudero, M.D., Juana Crespo, M.D., Carlos Simón, M.D., José Remohí, M.D., Antonio Pellicer, M.D.  Fertility and Sterility  Volume 80, Issue 6, Pages 1444-1449 (December 2003) DOI: 10.1016/j.fertnstert.2003.07.002

FIGURE 1 Area under the receiver-operating characteristic (ROC) curve for serum hormone measurements. (A) Serum E2 level. The area under the ROC curve was 0.534 (95% CI, 0.407 to 0.660). (B) Serum LH level. The area under the ROC curve was 0.581 (95% CI, 0.453 to 0.709). (C) Serum P level. The area under the ROC curve was 0.672 (95% CI, 0.555 to 0.789). The difference between these areas and the reference line (area 0.5) was statistically significant only for serum P level (P=.008). Bosch. Serum progesterone and IVF outcome. Fertil Steril 2003. Fertility and Sterility 2003 80, 1444-1449DOI: (10.1016/j.fertnstert.2003.07.002)